Debunking the Instant Myth of FDA as Rubber Stamp

2020-10-06T03:40:23-05:00

FDA's high approval rate for New Drug Applications (NDAs) is much in the news, with headlines like the one on a Matthew Herper post at Forbes: The FDA Is Basically Approving Everything. Here's the Data to Prove It. The data comes from an analysis that Forbes commissioned at BioMedTracker. When FDA approves 23 out of [...]

Debunking the Instant Myth of FDA as Rubber Stamp2020-10-06T03:40:23-05:00

Meeting the Challenges of Phase 2 Clinical Development

2020-10-06T03:44:19-05:00

Some investigational products successfully make the transition from phase 2 to phase 3 while most fall by the wayside. Disregarding products that fail because they simply lack efficacy or safety, what makes the difference between phase 2 success for a relative few products and failure for most? In our view, the key to maximizing chances [...]

Meeting the Challenges of Phase 2 Clinical Development2020-10-06T03:44:19-05:00
Go to Top